D. Doshi

发表

Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.

V. Sikirica, J. Schein, C. Benson, 2008, Clinical therapeutics.

Patient-Reported Experiences in Discussing Prescribed Medications with a Health Care Provider: Evidence for Racial/Ethnic Disparities in a Large Health Care Delivery System.

Sukyung Chung, R. Romanelli, J. LaMori, 2020, Population health management.

Role of Pimavanserin Treatment-Continuity on Discharge From Long-term Care: Assessing the Quality of Antipsychotic Medication Review.

K. Rajagopalan, D. Doshi, Damian May, 2022, The Senior care pharmacist.

The threshold rate of oral atypical anti-psychotic adherence at which paliperidone palmitate is cost saving

E. Muser, J. Fastenau, D. Doshi, 2012, Journal of medical economics.

Potential drug-drug interactions with antiepileptic drugs in Medicaid recipients.

M. Dickson, M. Rupnow, C. Kozma, 2008, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Patients' Medication-Related Experience of Care Is Associated with Adherence to Cardiometabolic Disease Therapy in Real-World Clinical Practice.

Sukyung Chung, R. Romanelli, J. LaMori, 2018, Population health management.

Effectiveness and tolerability of simeprevir and sofosbuvir in nontransplant and post‐liver transplant patients with hepatitis C genotype 1

Aijaz Ahmed, G. Garcia, M. Nguyen, 2016, Alimentary pharmacology & therapeutics.

Health care resource utilization and costs of California Medicaid patients with schizophrenia treated with paliperidone palmitate once monthly or atypical oral antipsychotic treatment

O. Baser, Li Wang, J. Pesa, 2017, Current medical research and opinion.

Comparative effectiveness of injectable paliperidone palmitate versus oral atypical antipsychotics: early postmarketing evidence.

E. Muser, E. Morrato, Deborah S K Thomas, 2015, Journal of comparative effectiveness research.

Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics

E. Muser, J. Fastenau, M. Duh, 2013, Journal of medical economics.

Health care resource utilization patterns among patients with Parkinson's disease psychosis: analysis of Medicare beneficiaries treated with Pimavanserin or other-atypical antipsychotics.

K. Rajagopalan, N. Rashid, D. Doshi, 2022, Journal of medical economics.

Reader Response: Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson Disease

D. Doshi, M. Turner, P. Subbiah, 2021, Neurology.

Evaluation of Resource Utilization and Cost Burden Before and After an Employer-Based Migraine Education Program

M. Rupnow, L. Paramore, D. Doshi, 2009, Journal of occupational and environmental medicine.

A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay*

W. Olson, V. Sikirica, J. Schein, 2008, Current medical research and opinion.

Patients treated with pimavanserin or quetiapine for Parkinson's disease psychosis: analysis of health resource utilization patterns among Medicare beneficiaries.

K. Rajagopalan, N. Rashid, D. Doshi, 2023, Journal of Medical Economics.

Original article Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics

E. Muser, J. Fastenau, M. Duh, 2013 .

Original article Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics

E. Muser, J. Fastenau, M. Duh, 2013 .